Effect of Xenon on Proinflammatory Activation and Apoptosis of Human Neutrophils Under Ex Vivo Conditions

Background. The syndrome of systemic inflammatory response, which underlies the damaging effect of factors of infectious and non-infectious genesis, may cause multiple organ failure. The degree of its severity is determined, among other things, by the activation of neutrophils. The paper highlights new mechanisms of the anti-inflammatory action of the inhalation anesthetic xenon, mediated by a decrease in the ability of neutrophils to pro-inflammatory response.
Aim of study. To evaluate the effect of xenon on the activation of human neutrophils under ex vivo conditions.
Material AND methods. We studied the effect of xenon inhalation on reduction of the ability of neutrophils to be activated proinflammatory by reduced expression of adhesion molecules CD11b and CD66b on the surface of neutrophils and on the phosphorylation of proinflammatory kinases: ERK 1/2 and kinase — p38 in neutrophils of healthy volunteers.
Results. The use of xenon at a dose of 30 vol. % within 60 minutes in healthy volunteers statistically significantly reduces the ability of neutrophils to proinflammatory activation. The addition of lipopolysaccharide (LPS) to the incubation medium of neutrophils causes their pronounced activation, statistically significantly increasing the phosphorylation of key proinflammatory neutrophil kinases ERK1/2 and kinase p38. Inhalation of xenon in volunteers (30% within 60 minutes) has a pronounced anti-inflammatory effect on LPS-stimulated neutrophils, decreasing their activation by inhibiting pro-inflammatory kinase ERK1/2 and pro-inflammatory MAP kinase p38.
Conclusion. The actual study, performed on isolated neutrophils from volunteers who underwent xenon inhalation, revealed the anti-inflammatory properties of the inert gas xenon, which, in our opinion, may have a direct relationship to the identification of the mechanism of its neuroprotective properties. Thus, the research results available today suggest that xenon has a pronounced pleiotropic mechanism of brain protection. This is a partial blockade of NMDA receptors, and phosphorylation of the enzyme glycogen synthase-3β, and limitation of the inflammatory activation of neutrophils.
Findings. Inhalation of xenon in volunteers (30% within 60 minutes) has a pronounced anti-inflammatory effect on neutrophils stimulated by lipopolysaccharides, decreasing their activation by inhibiting proinflammatory ERK 1/2 kinase and proinflammatory MAP kinase p38, as well as reducing the expression of markers of activation and degranulation CD11b and CD66b on the surface of neutrophils. Stimulation by lipopolysaccharides statistically significantly reduces spontaneous apoptosis of neutrophils, while xenon increases the ability of neutrophils to apoptosis, which is likely to contribute to the resolution of inflammation.

1. Balk RA. Systemic inflammatory response syndrome (SIRS): Where did it come from and is it still relevant today? Virulence. 2014;5(1):20–26. PMID: 24280933 https://doi.org/10.4161/viru.27135

2. Cheng Z, Abrams ST, Toh J, Wang SS, Wang Z, Yu Q, et al. The Critical Roles and Mechanisms of Immune Cell Death in Sepsis. Front Immunol. 2020;11:1918. PMID: 32983116 https://doi.org/10.3389/fimmu.2020.01918

3. Alexander JJ, Jacob A, Cunningham P, Hensley L, Quigg RJ. TNF is a key mediator of septic encephalopathy acting through its receptor, TNF receptor-1. Neurochem Int. 2008;52(3):447–456. PMID: 17884256 https://doi.org/10.1016/j.neuint.2007.08.00

4. Jaffer U, Wade RG, Gourlay T. Cytokines in the systemic inflammatory response syndrome: a review. HSR Proc Intensive Care Cardiovasc Anesth. 2010;2(3):161–175. PMID: 23441054

5. Guisasola MC, Alonso B, Bravo B, Vaquero J, Chana F. An overview of cytokines and heat shock response in polytraumatized patients. Cell Stress Chaperones. 2018;23(4):483–489. PMID: 29101529 https://doi.org/10.1007/s12192-017-0859-9

6. Schmidt T, Zündorf J, Grüger T, Brandenburg K, Reiners AL, Zinserling J, et al. CD66b overexpression and homotypic aggregation of human peripheral blood neutrophils after activation by a gram-positive stimulus. J Leukoc Biol. 2012;91(5):791–802. PMID: 22319104 https://doi.org/10.1189/jlb.0911483

7. Muller Kobold AC, Tulleken JE, Zijlstra JG, Sluiter W, Hermans J, Kallenberg CG, et al. Leukocyte activation in sepsis; correlations with disease state and mortality. Int Care Med. 2000;26(7):883–892. PMID: 10990102 https://doi.org/10.1007/s001340051277

8. Parkos CA, Colgan SP, Madara JL. Interactions of neutrophils with epithelial cells: lessons from the intestine. J Am Soc Nephrol. 1994;5(2):138–152. PMID: 7993993 https://doi.org/10.1681/ASN.V52138

9. Mortaz E, Zadian SS, Shahir M, Folkerts G, Garssen J, Mumby S, et al. Does Neutrophil Phenotype Predict the Survival of Trauma Patients? Front Immunol. 2019;10:2122. PMID: 31552051 https://doi.org/10.3389/fimmu.2019.02122

10. Pillay J, den Braber I, Vrisekoop N, Kwast LM, de Boer RJ, Borghans JA, et al. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood. 2010;116(4):625–627. PMID: 20410504 https://doi.org/10.1182/blood-2010-01-259028

11. Yuyun X, Fan Y, Weiping W, Qing Y, Bingwei S. Metabolomic analysis of spontaneous neutrophil apoptosis reveals the potential involvement of glutathione depletion. Innate Immun. 2021;27(1):31–40. PMID: 32910715 https://doi.org/10.1177/1753425920951985

12. Bartels M, Murphy K, Rieter E, Bruin M. Understanding chronic neutropenia: life is short. Br J Haematol. 2016;172(2):157–169. PMID: 26456767 https://doi.org/10.1111/bjh.13798

13. Collard CD, Park KA, Montalto MC, Alapati S, Buras JA, Stahl GL, Colgan SP. Neutrophil-derived glutamate regulates vascular endothelial barrier function. J Biol Chem. 2002;277(17):14801–14811. PMID: 11847215 https://doi.org/10.1074/jbc.M110557200

14. Kotz KT, Xiao W, Miller-Graziano C, Qian WJ, Russom A, Warner EA, et al. Clinical microfluidics for neutrophil genomics and proteomics. Nat Med. 2010;16(9):1042–1047. PMID: 20802500 https://doi.org/10.1038/nm.2205

15. Dorsett CR, McGuire JL, DePasquale EA, Gardner AE, Floyd CL, McCullumsmith RE. Glutamate Neurotransmission in Rodent Models of Traumatic Brain Injury. J Neurotrauma. 2017;34(2):263–272. PMID: 27256113 https://doi.org/10.1089/neu.2015.4373

16. Del Arroyo AG, Hadjihambi A, Sanchez J, Turovsky E, Kasymov V, Cain D, et al. NMDA receptor modulation of glutamate release in activated neutrophils. EBioMedicine. 2019;47:457–469. PMID: 31401196 https://doi.org/10.1016/j.ebiom.2019.08.004

17. de Sousa SL, Dickinson R, Lieb WR, Franks NP. Contrasting synaptic actions of the inhalational general anesthetics isoflurane and xenon. Anesthesiology. 2000;92(4):1055–1066. PMID: 10754626 https://doi.org/10.1097/00000542-200004000-00024

18. Grebenchikov OA, Molchanov IV, Shpichko AI, Yevseyev AK, Shabanov AK, Khusainov SZh, et al. Neuroprotective Properties of Xenon According to Experimental Studies. Russian Sklifosovsky Journal Emergency Medical Care. 2020;9(1):85–95. https://doi.org/10.23934/2223-9022-2020-9-1-85-95

19. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104–107. PMID: 20203610 https://doi.org/10.1038/nature08780

20. Campos-Pires R, Hirnet T, Valeo F, Ong BE, Radyushkin K, Aldhoun J, et al. Xenon improves long-term cognitive function, reduces neuronal loss and chronic neuroinflammation, and improves survival after traumatic brain injury in mice. Br J Anaesth. 2019;123(1):60–73. PMID: 31122738 https://doi.org/10.1016/j.bja.2019.02.032

21. Shpichko AI, Grebenchikov OA, Molchanov IV, Shabanov AK, Shpichko NP, Kadantseva KK. Cardioprotective Properties of Xenon. Russian Sklifosovsky Journal Emergency Medical Care. 2020;9(2):264–272. https://doi.org/10.23934/2223-9022-2020-9-2-264-272

22. Likhvantsev VV, Skripkin YuV, Grebenchikov OA, Shaposhnikov BA, Mironenko AV. Mekhanizmy deystviya i osnovnye effekty galogensoderzhashchikh anestetikov. Vestnik intensivnoy terapii. 2013;(3):44–51. (in Russ.).

23. Moroz VV, Likhvantsev VV, Grebenchikov OA. Current Trends in the Development of Anesthesiology. General Reanimatology. 2012;8(4):118. (in Russ.) https://doi.org/10.15360/1813-9779-2012-4-118

24. Moroz VV, Borisov KYu, Grebenchikov OA, Levikov DI, Shaibakova VL, Cherpakov RA, et al. Anesthetic-Induced Myocardial Preconditioning and Some Biochemical Markers for Cardiac and Coronary Failures after Aortocoronary Bypass Surgery. General Reanimatology. 2013;9(5):29. (In Russ.) https://doi.org/10.15360/1813-9779-2013-5-29

25. Grebenchikov OA, Skripkin YuV, Gerasimenko ON, Kadantseva KK, Bachinskiy AL, Berikashvili LB, et al. Non-anaesthetic effects of modern halogen-containing anaesthetics. Circulation Pathology and Cardiac Surgery. 2020;24(2):26–45. (In Russ.). http://dx.doi.org/10.21688/1681-3472-2020-2-26-45

26. Kuzovlev AN, Shpichko AI, Ryzhkov IA, Grebenchikov OA, Shabanov AK, Khusainov SZh, et al. Effect of Xenon on the Phosphorylation of Glycogen Synthase Kinase 3β and Antioxidant Enzymes in Rat Brain. Russian Sklifosovsky Journal Emergency Medical Care. 2020;9(4):564–572. https://doi.org/10.23934/2223-9022-2020-9-4-564-572

27. Grebenchikov OA, Avrushchenko MSh, Borisov KYu, Il’yin YuV, Likhvantsev VV. Neuroprotective effects of sevoflurane on the total ischemia-reperfusion model. Clinical Pathophysiology. 2014;(2):57–64. (in Russ.).

28. Piradov MA, Krylov VV, Belkin AA, Petrikov SS. Insul’ty. In: Gel’fand BR, Zabolotskikh IB (eds). Intensivnaya terapiya. Moscow: GEOTAR-Media Publ.; 2017. Ch. 2. pp. 288–309. (in Russ.).

29. Shabanov AK, Kartavenko VI, Petrikov SS, Marutyan ZG, Rozumny PA, Chernenkaya TV, et al. Severe Multisystem Craniocerebral Injury: Features of The Clinical Course and Outcomes. Russian Sklifosovsky Journal Emergency Medical Care. 2017;6(4):324–330. (in Russ.) https://doi.org/10.23934/2223-9022-2017-6-4-324-330